The Technical Analyst
Equillium Inc [EQ]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Equillium Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.35% $1.730
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 60.99 mill |
| EPS: | -0.380 |
| P/E: | -4.55 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 35.25 mill |
| Avg Daily Volume: | 0.374 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.55 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.77x |
| Company: PE -4.55 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.364 - 2.10 ( +/- 21.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Tom Penny | Sell | 0 | Common Stock |
| 2024-03-06 | Tom Penny | Sell | 45 000 | Employee Stock Option (right to buy) |
| 2024-03-06 | Tom Penny | Sell | 40 000 | Employee Stock Option (right to buy) |
| 2024-03-06 | Tom Penny | Sell | 60 000 | Employee Stock Option (right to buy) |
| 2024-03-06 | Tom Penny | Sell | 40 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 62.00 |
| Last 97 transactions |
| Buy: 3 858 069 | Sell: 577 250 |
Forecast:
16:00 - $1.730
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.730
Forecast 2: 16:00 - $1.730
Forecast 3: 16:00 - $1.730
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.730 (-3.35% ) |
| Volume | 0.0734 mill |
| Avg. Vol. | 0.374 mill |
| % of Avg. Vol | 19.63 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EQ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-03 08:00:00 - Press Release
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on april 1, 2024, the compensation committee of equillium's board of directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under equillium's 2024 inducement plan. the compensation committee ap.
2024-03-25 16:01:00 - Press Release
Equillium Reports On Fourth Quarter And Full Year 2023 Financial Results And Corporate And Clinical Highlights
La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights. “the past year we have been focused on clinical execution that has set up the potential milestones we have in front of us in 2024,” said b.
2024-03-22 08:00:00 - Press Release
Equillium To Present At The H.c. Wainwright Autoimmune & Inflammatory Disease Conference And The Ld Micro Invitational Conference
La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the h.c. wainwright autoimmune & inflammatory disease virtual conference, and the ld micro invitational conference. management will provide an overview of the company's clinical programs, partnership with ono pharmaceutical and 2024 milestones, during bot.
2023-12-21 08:00:00 - Press Release
Equillium Announces Update On Multi-cytokine Inhibitors Eq101 & Eq102 In Development For Alopecia Areata And Celiac Disease
La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced an update on multi-cytokine programs eq101 in development for the treatment of alopecia areata, eq102 in development for the treatment of celiac disease, and eq302, a new orally delivered multi-cytokine inhibitor. “we are pleased to have completed enrollment of the eq101 phase 2 stu.
2023-11-13 09:00:00 - Press Release
Equillium Presents Positive Data From Phase 1b Equalise Study At The 2023 Annual Meeting Of The American College Of Rheumatology
La jolla, calif.--(business wire)---- $eq #lupus--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the type b portion of the equalise study evaluating itolizumab in lupus nephritis patients was presented at acr convergence, the annual meeting of the american college of rheumatology (acr). the data presented by dr. kenneth kalunian, professor, medicine, ucsd school.
Latest News
2024-04-01 10:56:10 - Zacks Investment Research
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.
2024-03-25 18:10:23 - Zacks Investment Research
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago.
2024-03-22 08:00:00 - Business Wire
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference. Management will provide an overview of the company's clinical programs, partnership with Ono Pharmaceutical and 2024 milestones, during bot.
2024-03-01 10:31:19 - Zacks Investment Research
5 Stocks That More Than Doubled in February
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
2024-02-23 10:11:05 - Zacks Investment Research
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
2023-10-02 08:00:00 - Business Wire
Equillium to Present at the JonesTrading 2023 Healthcare Summit
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the JonesTrading 2023 Healthcare Summit taking place October 9 - 11 at the Eden Roc hotel in Miami, Florida. In addition to one-on-one investor meetings, management will participate in a panel presentation focused on industry trends that influence drug discov.
2023-08-09 18:59:08 - Zacks Investment Research
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.
2023-05-11 19:02:43 - Zacks Investment Research
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Equillium, Inc. (EQ) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.45 per share a year ago.
2022-11-08 08:00:00 - Business Wire
Equillium to Present at Two Upcoming Investor Conferences
2022-09-27 14:20:05 - InvestorPlace
Why Is Equillium (EQ) Stock Soaring 20% Today?
Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data regarding itolizumab. A monoclonal antibody, itolizumab aims to provide positive outcomes for patients suffering from lupus nephritis (or LN).